#1 Clinical Trials Search in Europe

Azd8630

AZD8630 is an experimental drug being studied for the treatment of asthma. This article summarizes the ongoing clinical trials evaluating the safety, effectiveness, and proper dosing of AZD8630 in healthy volunteers and patients with asthma. The trials aim to determine if AZD8630 can improve asthma control and reduce exacerbations when added to standard asthma medications.

Table of Contents

What is AZD8630?

AZD8630 is a new medication being developed for the treatment of asthma. It is currently undergoing clinical trials to evaluate its effectiveness and safety in managing asthma symptoms, particularly in patients with uncontrolled asthma who are at risk of exacerbations (sudden worsening of symptoms)[1].

How is AZD8630 Administered?

AZD8630 is administered through inhalation using a dry powder inhaler (DPI). This method of delivery allows the medication to be directly inhaled into the lungs, where it can act to improve asthma symptoms. The inhaler device is designed to be easy to use, making it convenient for patients to take their medication as prescribed[1][2].

Clinical Trials and Research

Several clinical trials are currently underway to evaluate the effectiveness and safety of AZD8630:

  • A Phase I study (NCT05110976) is investigating the safety, tolerability, and pharmacokinetics of AZD8630 in healthy adults and asthma patients[1].
  • A Phase IIb study (NCT06529419) called LEVANTE is assessing the efficacy and safety of multiple dose levels of AZD8630 in adults with uncontrolled asthma who are at risk of exacerbations[2].
  • Another study (NCT06531811) is comparing the bioavailability of AZD8630 using different inhaler devices[3].

These studies aim to determine the optimal dosage, effectiveness, and safety profile of AZD8630 for asthma treatment.

Potential Benefits

While research is still ongoing, AZD8630 shows promise in several areas:

  • Improved asthma control: The medication may help reduce asthma symptoms and improve lung function[2].
  • Reduced exacerbations: AZD8630 is being studied for its potential to decrease the frequency of asthma exacerbations, which can be serious and sometimes life-threatening[2].
  • Enhanced quality of life: By potentially improving asthma control, AZD8630 may lead to better overall quality of life for patients with asthma[2].

Safety and Side Effects

As with any new medication, the safety profile of AZD8630 is being carefully evaluated in clinical trials. Researchers are monitoring for potential side effects and adverse events. The studies include assessments of:

  • Number of participants experiencing adverse events[1][2]
  • Changes in vital signs and laboratory tests
  • Development of anti-drug antibodies (ADAs)[1]

It’s important to note that the full safety profile of AZD8630 will only be known after the completion of all clinical trials and regulatory review.

Future Prospects

AZD8630 represents a potential new option for asthma treatment, particularly for patients whose asthma is not well-controlled with current therapies. If the ongoing clinical trials demonstrate favorable results, AZD8630 could become an important addition to the arsenal of medications available for managing asthma.

As research progresses, more information will become available about the effectiveness, safety, and optimal use of AZD8630. Patients with asthma should continue to work closely with their healthcare providers to manage their condition and stay informed about new treatment options as they become available.

Aspect Details
Drug Name AZD8630
Administration Inhaled via dry powder inhaler
Target Condition Asthma
Trial Phases Phase 1 and Phase 2b
Study Populations Healthy volunteers and patients with asthma
Key Outcomes Safety, tolerability, pharmacokinetics, lung function, asthma control, exacerbations
Biomarkers Fractional exhaled nitric oxide (FeNO)
Comparator Placebo
Duration 2-12 weeks of treatment in various trials

FAQ

  • What is AZD8630? AZD8630 is an investigational drug being studied as a potential new treatment for asthma. It is administered via inhalation using a dry powder inhaler device.
  • What are the main goals of the AZD8630 clinical trials? The main goals are to evaluate the safety, tolerability, effectiveness, and proper dosing of AZD8630 in both healthy volunteers and patients with asthma. The trials aim to determine if AZD8630 can improve asthma control and reduce exacerbations when added to standard asthma medications.
  • How is AZD8630 given to patients in the trials? AZD8630 is given via inhalation using a dry powder inhaler device. Patients inhale the medication once daily in most of the trials.
  • What types of patients are being included in the AZD8630 trials? The trials are including both healthy volunteers and patients with asthma. Some trials focus on patients with uncontrolled asthma who are at risk of exacerbations despite using standard asthma medications like inhaled corticosteroids and long-acting beta-agonists.
  • What are some of the key outcomes being measured in the trials? Key outcomes include safety measures like adverse events, measures of lung function like FEV1, asthma control questionnaires, quality of life assessments, time to asthma exacerbations, and biomarkers of inflammation like fractional exhaled nitric oxide (FeNO).

Ongoing Clinical Trials on Azd8630

  • Study on the Safety and Effectiveness of AZD8630 for Adults with Uncontrolled Asthma at Risk of Exacerbations

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Italy +3

Glossary

  • Asthma: A chronic lung disease that inflames and narrows the airways, causing recurring periods of wheezing, chest tightness, shortness of breath, and coughing.
  • Exacerbation: A worsening of asthma symptoms that may require additional treatment or hospitalization.
  • Inhaled corticosteroids (ICS): Anti-inflammatory medications inhaled directly into the lungs to reduce airway inflammation in asthma.
  • Long-acting beta-agonists (LABA): Medications that relax the muscles around the airways to keep them open for long periods, usually used in combination with inhaled corticosteroids for asthma control.
  • Forced expiratory volume in 1 second (FEV1): A measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • Fractional exhaled nitric oxide (FeNO): A biomarker of airway inflammation measured in exhaled breath, often elevated in asthma.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of a drug's effects on the body and how it works at target sites.
  • Dry powder inhaler (DPI): A device used to deliver medication in a dry powder form directly to the lungs through inhalation.
  • Anti-drug antibodies (ADAs): Antibodies produced by the immune system in response to a therapeutic drug, which can potentially affect the drug's efficacy or safety.

References